---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-003795"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:46:08.506974+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sana reports Q4 net loss $80.4M; cash $434M; SC291 IND cleared, expects clinical data this year

## Summary
- Net loss Q4 2022 $80.4M ($0.42/sh) vs $110.7M ($0.60/sh) in Q4 2021; FY2022 net loss $269.5M ($1.43/sh).
- Cash and marketable securities $434.0M at Dec 31, 2022, down from $746.9M; cash runway into 2025.
- SC291 (CD19-targeted allogeneic CAR T) IND cleared; initial clinical data expected in 2023.
- Plans to move manufacturing to Bothell, WA; expects ~$100M cost savings versus Fremont build-out.
- Non-GAAP operating cash burn FY2022 $288.3M vs $209.6M; restructuring costs in Q4 2022.

## SEC filing metadata
- accession: 0001564590-23-003795
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000156459023003795/0001564590-23-003795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000156459023003795/sana-8k_20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-003795
- JSON: https://secwatch.observer/filing/0001564590-23-003795.json
- Plain text: https://secwatch.observer/filing/0001564590-23-003795.txt

## Key facts
- Earnings Releases
  Sana Biotechnology, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 16, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000156459023003795/0001564590-23-003795-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.